Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

BACKGROUND: Trastuzumab with cisplatin and fluoropyrimidine is the standard treatment in metastatic HER2-positive gastric or gastroesophageal (GE) junction adenocarcinoma, however there is limited data on the efficacy of trastuzumab in combination with a three-drug regimen in this setting. We examin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Gastric Cancer
Hlavní autoři: Mondaca, Sebastian, Margolis, Matthew, Sanchez-Vega, Francisco, Jonsson, Philip, Riches, Jamie C., Ku, Geoffrey Y., Hechtman, Jaclyn F., Tuvy, Yaelle, Berger, Michael F., Shah, Manish A., Kelsen, David P., Ilson, David H., Yu, Kenneth, Goldberg, Zoe, Epstein, Andrew S., Desai, Avni, Chung, Vincent, Chou, Joanne F., Capanu, Marinela, Solit, David B., Schultz, Nikolaus, Janjigian, Yelena Y.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784321/
https://ncbi.nlm.nih.gov/pubmed/30088161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10120-018-0861-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky